Huan Mo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Huan Mo has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Joshua C. Denny
National Institutes of Health
12 shared publications Peter Speltz
Department of Biomedical Informatics, Vanderbilt University, Nashville, TN, USA
5 shared publications- Bennett J. Waxse
Precision Health Informatics Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA
4 shared publications Enid Montague
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; School of Computing, DePaul University, Chicago, IL, USA
4 shared publicationsJoshua C Denny
Precision Health Informatics Section, National Human Genome Research Institute, National Institutes of Health , Bethesda, MD, United States
4 shared publicationsJyotishman Pathak
Division of Health Informatics, Weill Cornell Medical College, Cornell University, New York City, NY, USA
4 shared publications
Latest Publications
- Open Access
11 million days of longitudinal wearable data reveal novel future health insights
Background: Insufficient physical activity (PA) is associated with higher risk of morbidity and premature mortality. Wearable devices offer a scalable, objective measurement of physical activity, but most studies reduce these data to a single activity metric measured over a fixed 7-day period. We compared different wearable-derived phenotyping approaches to understand their impact on activity-disease associations. Methods: We analyzed 11 million days of Fitbit data from 29,351 participants in the All of Us Research Program, deriving four daily activity metrics (step count, peak 1-min cadence, peak 30-min cadence, and heart rate per step) across five time-windows (1-day, 1-week, 1-month, 6-months, 1-year). We performed phenome-wide analyses on >700 incident and >1,300 prevalent disease outcomes identified from linked electronic health records. Findings: Among participants with EHR and Fitbit data (mean age 57.3 years, 69% female, 47% with >1 year of Fitbit data), all 20 phenotypes were highly correlated (median Pearson r = 0.71). Longer measurement windows yielded stronger and more stable associations, with 1-year step count associated with 373 prevalent and 37 incident outcomes (versus 231 and 17 for 1-day step count) after Bonferroni-correction, including novel associations with chronic pain syndrome, SARS-CoV-2, and autoimmune disease. Differences between prevalent and incident associations suggest that activity metrics can act as both early markers of disease or risk factors. Interpretation: These findings highlight how large-scale, longitudinal wearable data can advance understanding of health and disease and inform scalable approaches for clinical risk stratification. Funding: National Institutes of Health Intramural Research Program, Wellcome Trust RESEARCH IN CONTEXT: Evidence before this study: Low levels of physical activity relate to numerous health outcomes. However, prior studies are limited by a focus on disease prevalence and by a lack of examination across a broad range of health outcomes. Further, the strength of these associations, depends on how physical activity is measured. Prior work shows that wearable devices capture activity more reliably than self-report surveys and typically yield stronger associations with disease risk. Most wearable-based studies rely on short monitoring windows: often seven days or fewer. To our knowledge, no study has systematically evaluated how the duration of wearable-based phenotyping influences estimates of disease risk. To explore this, we searched PubMed using the terms “wearable phenotyping” AND “disease risk”, resulting in 48 articles published between 2016 and 2025. Although some studies compared different wearable-derived phenotypes (e.g., step count vs. sleep duration) or explored how the number of observed days affects data quality, none directly evaluated how the length of the phenotyping period shapes associations with disease risk. Added value of this study: Using nearly 11 million person-days of Fitbit data from ∼30,000 participants, this study evaluates how four wearable-derived activity metrics, summarized across five time windows, influence estimates of activity-disease associations. We identified over 300 previously unreported associations for any of our four metrics and various health outcomes. Longer phenotyping windows consistently yielded stronger associations than shorter ones, although all windows remained informative. These findings highlight the importance of extended wearable monitoring for robust risk characterization. We further compared incident cases with both prevalent and incident outcomes, illustrating the roles of physical activity as a potentially modifiable risk factor, and an early marker of disease. Implications of all the available evidence: These findings have two important implications. First, longer periods of wearable data collection improve the accuracy of disease risk estimation and should be considered in the design of epidemiologic studies and in the development of clinical guidelines. Although associations between physical activity and disease were directionally consistent across all time windows, effect sizes varied substantially, an observation with important consequences for public health recommendations. Second, this study represents one of the first large-scale demonstrations of long-term wearable monitoring for real-world risk stratification, marking an important advance toward individualized health assessment and intervention.
Open Access11 million days of longitudinal wearable data reveal novel future health insights
Background: Insufficient physical activity (PA) is associated with higher risk of morbidity and premature mortality. Wearable devices offer a scalable, objective measurement of physical activity, but most studies reduce these data to a single activity metric measured over a fixed 7-day period. We compared different wearable-derived phenotyping approaches to understand their impact on activity-disease associations. Methods: We analyzed 11 million days of Fitbit data from 29,351 participants in the All of Us Research Program, deriving four daily activity metrics (step count, peak 1-min cadence, peak 30-min cadence, and heart rate per step) across five time-windows (1-day, 1-week, 1-month, 6-months, 1-year). We performed phenome-wide analyses on >700 incident and >1,300 prevalent disease outcomes identified from linked electronic health records. Findings: Among participants with EHR and Fitbit data (mean age 57.3 years, 69% female, 47% with >1 year of Fitbit data), all 20 phenotypes were highly correlated (median Pearson r = 0.71). Longer measurement windows yielded stronger and more stable associations, with 1-year step count associated with 373 prevalent and 37 incident outcomes (versus 231 and 17 for 1-day step count) after Bonferroni-correction, including novel associations with chronic pain syndrome, SARS-CoV-2, and autoimmune disease. Differences between prevalent and incident associations suggest that activity metrics can act as both early markers of disease or risk factors. Interpretation: These findings highlight how large-scale, longitudinal wearable data can advance understanding of health and disease and inform scalable approaches for clinical risk stratification. Funding: National Institutes of Health Intramural Research Program, Wellcome Trust RESEARCH IN CONTEXT: Evidence before this study: Low levels of physical activity relate to numerous health outcomes. However, prior studies are limited by a focus on disease prevalence and by a lack of examination across a broad range of health outcomes. Further, the strength of these associations, depends on how physical activity is measured. Prior work shows that wearable devices capture activity more reliably than self-report surveys and typically yield stronger associations with disease risk. Most wearable-based studies rely on short monitoring windows: often seven days or fewer. To our knowledge, no study has systematically evaluated how the duration of wearable-based phenotyping influences estimates of disease risk. To explore this, we searched PubMed using the terms “wearable phenotyping” AND “disease risk”, resulting in 48 articles published between 2016 and 2025. Although some studies compared different wearable-derived phenotypes (e.g., step count vs. sleep duration) or explored how the number of observed days affects data quality, none directly evaluated how the length of the phenotyping period shapes associations with disease risk. Added value of this study: Using nearly 11 million person-days of Fitbit data from ∼30,000 participants, this study evaluates how four wearable-derived activity metrics, summarized across five time windows, influence estimates of activity-disease associations. We identified over 300 previously unreported associations for any of our four metrics and various health outcomes. Longer phenotyping windows consistently yielded stronger associations than shorter ones, although all windows remained informative. These findings highlight the importance of extended wearable monitoring for robust risk characterization. We further compared incident cases with both prevalent and incident outcomes, illustrating the roles of physical activity as a potentially modifiable risk factor, and an early marker of disease. Implications of all the available evidence: These findings have two important implications. First, longer periods of wearable data collection improve the accuracy of disease risk estimation and should be considered in the design of epidemiologic studies and in the development of clinical guidelines. Although associations between physical activity and disease were directionally consistent across all time windows, effect sizes varied substantially, an observation with important consequences for public health recommendations. Second, this study represents one of the first large-scale demonstrations of long-term wearable monitoring for real-world risk stratification, marking an important advance toward individualized health assessment and intervention.
- Open Access
Computable Phenotypes for Respiratory Viral Infections in the All of Us Research Program
Electronic health records (EHRs) contain rich temporal data about infectious diseases, but an optimal approach to identify infections remains undefined. Using the All of Us Research Program, we developed computable phenotypes for respiratory viruses by integrating billing codes, prescriptions, and laboratory results within 90-day episodes. Phenotypes computed from 265,222 participants yielded cohorts ranging from 238 (adenovirus) to 28,729 (SARS-CoV-2) cases. Virus-specific billing codes showed varied sensitivity (8-67%) and high positive predictive value (90-97%), except for influenza virus and SARS-CoV-2 where lower PPV (69-70%) improved with increasing billing codes. Identified infections exhibited expected seasonal patterns and virus proportions when compared with CDC data. This integrated approach identified episodic disease more effectively than individual components alone and demonstrated utility in identifying severe infections. The method enables large-scale studies of host genetics, health disparities, and clinical outcomes across episodic diseases.
Open AccessComputable Phenotypes for Respiratory Viral Infections in the All of Us Research Program
Electronic health records (EHRs) contain rich temporal data about infectious diseases, but an optimal approach to identify infections remains undefined. Using the All of Us Research Program, we developed computable phenotypes for respiratory viruses by integrating billing codes, prescriptions, and laboratory results within 90-day episodes. Phenotypes computed from 265,222 participants yielded cohorts ranging from 238 (adenovirus) to 28,729 (SARS-CoV-2) cases. Virus-specific billing codes showed varied sensitivity (8-67%) and high positive predictive value (90-97%), except for influenza virus and SARS-CoV-2 where lower PPV (69-70%) improved with increasing billing codes. Identified infections exhibited expected seasonal patterns and virus proportions when compared with CDC data. This integrated approach identified episodic disease more effectively than individual components alone and demonstrated utility in identifying severe infections. The method enables large-scale studies of host genetics, health disparities, and clinical outcomes across episodic diseases.
- Open Access
- 14 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 534-543
Hyponatremia Associated with the Use of Common Antidepressants in the All of Us Research Program
Selective serotonin reuptake inhibitor (SSRI), serotonin‐norepinephrine reuptake inhibitor (SNRI), and norepinephrine–dopamine reuptake inhibitor (NRI) antidepressants can cause hyponatremia through syndrome of inappropriate antidiuretic hormone secretion (SIADH). This study assesses the differential risks of hyponatremia associated with commonly prescribed SSRIs (fluoxetine, paroxetine, sertraline, citalopram, escitalopram), SNRIs (duloxetine, venlafaxine) and NRI (bupropion), as well as omeprazole as a reference, with a retrospective observational cohort study in the All of Us Research Program, a national multicenter research cohort containing de‐identified electronic health records (EHR). Participants who had been prescribed monotherapy with any of eight common antidepressants were included, with each drug considered as a separate arm indexed with a start date. Events were defined as the first occurrence of a low plasma sodium measurement or a clinical diagnosis recorded for either hyponatremia or SIADH. Those who did not have events were censored at their last plasma sodium measurement. A total of 17,439 individuals were exposed to one of the eight antidepressants as monotherapy. The overall incidences for hyponatremia were 0.87% in the first 30 days and 10.5% in the first 3 years in the antidepressant arms. Compared to sertraline, duloxetine (hazard ratio [HR] = 1.37 [1.19–1.58]) and escitalopram (HR = 1.16 [1.01–1.33]) were associated with the highest overall risk of hyponatremia, and bupropion (HR = 0.83 [0.73–0.94]) and paroxetine (HR = 0.78 [0.65–0.93]) were associated with the lowest risk. The risks were unchanged after adjusting for comorbidity and polypharmacy. Such information could help guide providers in managing patients and their risks of hyponatremia when on common antidepressants.
- 14 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 534-543
Open AccessHyponatremia Associated with the Use of Common Antidepressants in the All of Us Research Program
Selective serotonin reuptake inhibitor (SSRI), serotonin‐norepinephrine reuptake inhibitor (SNRI), and norepinephrine–dopamine reuptake inhibitor (NRI) antidepressants can cause hyponatremia through syndrome of inappropriate antidiuretic hormone secretion (SIADH). This study assesses the differential risks of hyponatremia associated with commonly prescribed SSRIs (fluoxetine, paroxetine, sertraline, citalopram, escitalopram), SNRIs (duloxetine, venlafaxine) and NRI (bupropion), as well as omeprazole as a reference, with a retrospective observational cohort study in the All of Us Research Program, a national multicenter research cohort containing de‐identified electronic health records (EHR). Participants who had been prescribed monotherapy with any of eight common antidepressants were included, with each drug considered as a separate arm indexed with a start date. Events were defined as the first occurrence of a low plasma sodium measurement or a clinical diagnosis recorded for either hyponatremia or SIADH. Those who did not have events were censored at their last plasma sodium measurement. A total of 17,439 individuals were exposed to one of the eight antidepressants as monotherapy. The overall incidences for hyponatremia were 0.87% in the first 30 days and 10.5% in the first 3 years in the antidepressant arms. Compared to sertraline, duloxetine (hazard ratio [HR] = 1.37 [1.19–1.58]) and escitalopram (HR = 1.16 [1.01–1.33]) were associated with the highest overall risk of hyponatremia, and bupropion (HR = 0.83 [0.73–0.94]) and paroxetine (HR = 0.78 [0.65–0.93]) were associated with the lowest risk. The risks were unchanged after adjusting for comorbidity and polypharmacy. Such information could help guide providers in managing patients and their risks of hyponatremia when on common antidepressants.
- Open Access
- 25 July 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (6) , 1544-1553
Racial and Ethnic Disparities in Antihypertensive Medication Prescribing Patterns and Effectiveness
Variability in drug effectiveness and provider prescribing patterns have been reported in different racial and ethnic populations. We sought to evaluate antihypertensive drug effectiveness and prescribing patterns among self‐identified Hispanic/Latino (Hispanic), Non‐Hispanic Black (Black), and Non‐Hispanic White (White) populations that enrolled in the NIH All of Us Research Program, a US longitudinal cohort. We employed a self‐controlled case study method using electronic health record and survey data from 17,718 White, Hispanic, and Black participants who were diagnosed with essential hypertension and prescribed at least one of 19 commonly used antihypertensive medications. Effectiveness was determined by calculating the reduction in systolic blood pressure measurements after 28 or more days of drug exposure. Starting systolic blood pressure and effectiveness for each medication were compared for self‐reported Black, Hispanic, and White participants using adjusted linear regressions. Black and Hispanic participants were started on antihypertensive medications at significantly higher SBP than White participants in 13 and 7 out of 19 medications, respectively. More Black participants were prescribed multiple antihypertensive medications (58.46%) than White (52.35%) or Hispanic (49.9%) participants. First‐line HTN medications differed by race and ethnicity. Following the 2017 American College of Cardiology and the American Heart Association High Blood Pressure Guideline release, around 64% of Black participants were prescribed a recommended first‐line antihypertensive drug compared with 76% of White and 82% of Hispanic participants. Effect sizes suggested that most antihypertensive drugs were less effective in Hispanic and Black, compared with White, participants, and statistical significance was reached in 6 out of 19 drugs. These results indicate that Black and Hispanic populations may benefit from earlier intervention and screening and highlight the potential benefits of personalizing first‐line medications.
- 25 July 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (6) , 1544-1553
Open AccessRacial and Ethnic Disparities in Antihypertensive Medication Prescribing Patterns and Effectiveness
Variability in drug effectiveness and provider prescribing patterns have been reported in different racial and ethnic populations. We sought to evaluate antihypertensive drug effectiveness and prescribing patterns among self‐identified Hispanic/Latino (Hispanic), Non‐Hispanic Black (Black), and Non‐Hispanic White (White) populations that enrolled in the NIH All of Us Research Program, a US longitudinal cohort. We employed a self‐controlled case study method using electronic health record and survey data from 17,718 White, Hispanic, and Black participants who were diagnosed with essential hypertension and prescribed at least one of 19 commonly used antihypertensive medications. Effectiveness was determined by calculating the reduction in systolic blood pressure measurements after 28 or more days of drug exposure. Starting systolic blood pressure and effectiveness for each medication were compared for self‐reported Black, Hispanic, and White participants using adjusted linear regressions. Black and Hispanic participants were started on antihypertensive medications at significantly higher SBP than White participants in 13 and 7 out of 19 medications, respectively. More Black participants were prescribed multiple antihypertensive medications (58.46%) than White (52.35%) or Hispanic (49.9%) participants. First‐line HTN medications differed by race and ethnicity. Following the 2017 American College of Cardiology and the American Heart Association High Blood Pressure Guideline release, around 64% of Black participants were prescribed a recommended first‐line antihypertensive drug compared with 76% of White and 82% of Hispanic participants. Effect sizes suggested that most antihypertensive drugs were less effective in Hispanic and Black, compared with White, participants, and statistical significance was reached in 6 out of 19 drugs. These results indicate that Black and Hispanic populations may benefit from earlier intervention and screening and highlight the potential benefits of personalizing first‐line medications.
- Open Access
- 26 October 2023
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 31 (1) , 139-153
Systematic replication of smoking disease associations using survey responses and EHR data in the All of Us Research Program
The All of Us Research Program (All of Us) aims to recruit over a million participants to further precision medicine. Essential to the verification of biobanks is a replication of known associations to establish validity. Here, we evaluated how well All of Us data replicated known cigarette smoking associations. We defined smoking exposure as follows: (1) an EHR Smoking exposure that used International Classification of Disease codes; (2) participant provided information (PPI) Ever Smoking; and, (3) PPI Current Smoking, both from the lifestyle survey. We performed a phenome-wide association study (PheWAS) for each smoking exposure measurement type. For each, we compared the effect sizes derived from the PheWAS to published meta-analyses that studied cigarette smoking from PubMed. We defined two levels of replication of meta-analyses: (1) nominally replicated: which required agreement of direction of effect size, and (2) fully replicated: which required overlap of confidence intervals. PheWASes with EHR Smoking, PPI Ever Smoking, and PPI Current Smoking revealed 736, 492, and 639 phenome-wide significant associations, respectively. We identified 165 meta-analyses representing 99 distinct phenotypes that could be matched to EHR phenotypes. At P < .05, 74 were nominally replicated and 55 were fully replicated. At P < 2.68 × 10−5 (Bonferroni threshold), 58 were nominally replicated and 40 were fully replicated. Most phenotypes found in published meta-analyses associated with smoking were nominally replicated in All of Us. Both survey and EHR definitions for smoking produced similar results. This study demonstrated the feasibility of studying common exposures using All of Us data.
- 26 October 2023
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 31 (1) , 139-153
Open AccessSystematic replication of smoking disease associations using survey responses and EHR data in the All of Us Research Program
The All of Us Research Program (All of Us) aims to recruit over a million participants to further precision medicine. Essential to the verification of biobanks is a replication of known associations to establish validity. Here, we evaluated how well All of Us data replicated known cigarette smoking associations. We defined smoking exposure as follows: (1) an EHR Smoking exposure that used International Classification of Disease codes; (2) participant provided information (PPI) Ever Smoking; and, (3) PPI Current Smoking, both from the lifestyle survey. We performed a phenome-wide association study (PheWAS) for each smoking exposure measurement type. For each, we compared the effect sizes derived from the PheWAS to published meta-analyses that studied cigarette smoking from PubMed. We defined two levels of replication of meta-analyses: (1) nominally replicated: which required agreement of direction of effect size, and (2) fully replicated: which required overlap of confidence intervals. PheWASes with EHR Smoking, PPI Ever Smoking, and PPI Current Smoking revealed 736, 492, and 639 phenome-wide significant associations, respectively. We identified 165 meta-analyses representing 99 distinct phenotypes that could be matched to EHR phenotypes. At P < .05, 74 were nominally replicated and 55 were fully replicated. At P < 2.68 × 10−5 (Bonferroni threshold), 58 were nominally replicated and 40 were fully replicated. Most phenotypes found in published meta-analyses associated with smoking were nominally replicated in All of Us. Both survey and EHR definitions for smoking produced similar results. This study demonstrated the feasibility of studying common exposures using All of Us data.
- Open Access
- 8 June 2023
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 47 (8) , 849-858
Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features
The blastoid (B) and pleomorphic (P) variants of mantle cell lymphoma (MCL) are associated with aggressive clinical behavior. In this study, we collected 102 cases of B-MCL and P-MCL from untreated patients. We reviewed clinical data, analyzed morphologic features using an image analysis tool (ImageJ) and we assessed mutational and gene expression profiles. The chromatin pattern of lymphoma cells was assessed quantitatively by the pixel value. Cases of B-MCL showed a greater median pixel value with lower variation compared with P-MCL, indicating a homogeneously euchromatin-rich pattern in B-MCL. In addition, the Feret diameter of the nuclei was significantly smaller (median 6.92 vs. 8.49 µm per nucleus, PP=0.003), and affected patients had poorer overall survival compared with those with P-MCL (median overall survival: 3.1 vs. 8.8 y, respectively, P=0.038). NOTCH1 mutation was significantly more frequent in B-MCL compared with P-MCL (33% and 0%, respectively, P=0.004). Gene expression profiling showed 14 genes overexpressed in B-MCL cases and gene set enrichment assay for the overexpressed genes showed significant enrichment in the cell cycle and mitotic transition pathways. We also report a subset of MCL cases that has blastoid chromatin but a higher degree of pleomorphism in nuclear size and shape, designated here as hybrid MCL. Hybrid MCL cases had a similar Ki-67 proliferation rate, mutation profile, and clinical outcome to B-MCL and distinct from P-MCL. In summary, these data suggest biological differences between B-MCL and P-MCL cases justifying their separate designation when possible.
- 8 June 2023
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 47 (8) , 849-858
Open AccessBlastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features
The blastoid (B) and pleomorphic (P) variants of mantle cell lymphoma (MCL) are associated with aggressive clinical behavior. In this study, we collected 102 cases of B-MCL and P-MCL from untreated patients. We reviewed clinical data, analyzed morphologic features using an image analysis tool (ImageJ) and we assessed mutational and gene expression profiles. The chromatin pattern of lymphoma cells was assessed quantitatively by the pixel value. Cases of B-MCL showed a greater median pixel value with lower variation compared with P-MCL, indicating a homogeneously euchromatin-rich pattern in B-MCL. In addition, the Feret diameter of the nuclei was significantly smaller (median 6.92 vs. 8.49 µm per nucleus, PP=0.003), and affected patients had poorer overall survival compared with those with P-MCL (median overall survival: 3.1 vs. 8.8 y, respectively, P=0.038). NOTCH1 mutation was significantly more frequent in B-MCL compared with P-MCL (33% and 0%, respectively, P=0.004). Gene expression profiling showed 14 genes overexpressed in B-MCL cases and gene set enrichment assay for the overexpressed genes showed significant enrichment in the cell cycle and mitotic transition pathways. We also report a subset of MCL cases that has blastoid chromatin but a higher degree of pleomorphism in nuclear size and shape, designated here as hybrid MCL. Hybrid MCL cases had a similar Ki-67 proliferation rate, mutation profile, and clinical outcome to B-MCL and distinct from P-MCL. In summary, these data suggest biological differences between B-MCL and P-MCL cases justifying their separate designation when possible.
- 20 July 2022
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 81 (9) , 707-716
Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas
Isocitrate dehydrogenase (IDH) mutant gliomas are associated with a better prognosis in comparison to adult IDH wild-type glioma and glioma-CpG island methylator phenotypes. Although OLIG2 is mainly expressed in oligodendrocytes in normal adult brain, it is expressed in both astrocytomas and oligodendrogliomas. Utilizing the clinical, DNA methylation, and RNA-sequencing data from the Cancer Genome Atlas (TCGA) for lower-grade glioma and glioblastoma cohorts, we explored the association between IDH mutation status and OLIG2 expression on transcription, DNA methylation, and gene target levels. Compared to IDH wild-type gliomas, IDH mutant gliomas showed consistently higher expression of OLIG2 transcripts. OLIG2 overexpression is a good surrogate marker for IDH mutation with an AUC of 0.90. At the DNA methylation level, IDH-mutant gliomas showed hyper- and hypomethylation foci upstream of the OLIG2 transcription start site. Underexpressed OLIG2 target genes in IDH mutant glioma were enriched in cell cycle-related pathways. Thus, the differential expression of OLIG2 between IDH mutant and wild-type gliomas reflects involvement in multiple pathways in tumorigenesis.
- 20 July 2022
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 81 (9) , 707-716
Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas
Isocitrate dehydrogenase (IDH) mutant gliomas are associated with a better prognosis in comparison to adult IDH wild-type glioma and glioma-CpG island methylator phenotypes. Although OLIG2 is mainly expressed in oligodendrocytes in normal adult brain, it is expressed in both astrocytomas and oligodendrogliomas. Utilizing the clinical, DNA methylation, and RNA-sequencing data from the Cancer Genome Atlas (TCGA) for lower-grade glioma and glioblastoma cohorts, we explored the association between IDH mutation status and OLIG2 expression on transcription, DNA methylation, and gene target levels. Compared to IDH wild-type gliomas, IDH mutant gliomas showed consistently higher expression of OLIG2 transcripts. OLIG2 overexpression is a good surrogate marker for IDH mutation with an AUC of 0.90. At the DNA methylation level, IDH-mutant gliomas showed hyper- and hypomethylation foci upstream of the OLIG2 transcription start site. Underexpressed OLIG2 target genes in IDH mutant glioma were enriched in cell cycle-related pathways. Thus, the differential expression of OLIG2 between IDH mutant and wild-type gliomas reflects involvement in multiple pathways in tumorigenesis.
- Open Access
- 1 December 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (12) , 2183-2191
EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
- 1 December 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (12) , 2183-2191
Open AccessEZH2 expression is associated with inferior overall survival in mantle cell lymphoma
- 1 April 2017
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 58 (3) , 127-139
Effects of G6pc2 deletion on body weight and cholesterol in mice
Genome-wide association study (GWAS) data have linked the G6PC2 gene to variations in fasting blood glucose (FBG). G6PC2 encodes an islet-specific glucose-6-phosphatase catalytic subunit that forms a substrate cycle with the beta cell glucose sensor glucokinase. This cycle modulates the glucose sensitivity of insulin secretion and hence FBG. GWAS data have not linked G6PC2 to variations in body weight but we previously reported that female C57BL/6J G6pc2-knockout (KO) mice were lighter than wild-type littermates on both a chow and high-fat diet. The purpose of this study was to compare the effects of G6pc2 deletion on FBG and body weight in both chow-fed and high-fat-fed mice on two other genetic backgrounds. FBG was reduced in G6pc2 KO mice largely independent of gender, genetic background or diet. In contrast, the effect of G6pc2 deletion on body weight was markedly influenced by these variables. Deletion of G6pc2 conferred a marked protection against diet-induced obesity in male mixed genetic background mice, whereas in 129SvEv mice deletion of G6pc2 had no effect on body weight. G6pc2 deletion also reduced plasma cholesterol levels in a manner dependent on gender, genetic background and diet. An association between G6PC2 and plasma cholesterol was also observed in humans through electronic health record-derived phenotype analyses. These observations suggest that the action of G6PC2 on FBG is largely independent of the influences of environment, modifier genes or epigenetic events, whereas the action of G6PC2 on body weight and cholesterol are influenced by unknown variables.
- 1 April 2017
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 58 (3) , 127-139
Effects of G6pc2 deletion on body weight and cholesterol in mice
Genome-wide association study (GWAS) data have linked the G6PC2 gene to variations in fasting blood glucose (FBG). G6PC2 encodes an islet-specific glucose-6-phosphatase catalytic subunit that forms a substrate cycle with the beta cell glucose sensor glucokinase. This cycle modulates the glucose sensitivity of insulin secretion and hence FBG. GWAS data have not linked G6PC2 to variations in body weight but we previously reported that female C57BL/6J G6pc2-knockout (KO) mice were lighter than wild-type littermates on both a chow and high-fat diet. The purpose of this study was to compare the effects of G6pc2 deletion on FBG and body weight in both chow-fed and high-fat-fed mice on two other genetic backgrounds. FBG was reduced in G6pc2 KO mice largely independent of gender, genetic background or diet. In contrast, the effect of G6pc2 deletion on body weight was markedly influenced by these variables. Deletion of G6pc2 conferred a marked protection against diet-induced obesity in male mixed genetic background mice, whereas in 129SvEv mice deletion of G6pc2 had no effect on body weight. G6pc2 deletion also reduced plasma cholesterol levels in a manner dependent on gender, genetic background and diet. An association between G6PC2 and plasma cholesterol was also observed in humans through electronic health record-derived phenotype analyses. These observations suggest that the action of G6PC2 on FBG is largely independent of the influences of environment, modifier genes or epigenetic events, whereas the action of G6PC2 on body weight and cholesterol are influenced by unknown variables.